Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Sota J., Breda L., Paroli M. P., Hashad S., de-la-Torre A., Guerriero S., ...Daha Fazla

BRITISH JOURNAL OF OPHTHALMOLOGY, cilt.109, sa.10, ss.1151-1154, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 109 Sayı: 10
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1136/bjo-2025-327410
  • Dergi Adı: BRITISH JOURNAL OF OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
  • Sayfa Sayıları: ss.1151-1154
  • Gazi Üniversitesi Adresli: Evet

Özet

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.